100 related articles for article (PubMed ID: 11272282)
1. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
Nemoto K; Shibamoto Y; Ohmagari J; Baba Y; Ebe K; Ariga H; Takai Y; Ouchi A; Sasai K; Shinozaki M; Tsujitani M; Sakaguchi M; Yamada S; Sakamoto K
Anticancer Drugs; 2001 Jan; 12(1):1-6. PubMed ID: 11272282
[TBL] [Abstract][Full Text] [Related]
2. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
Yahiro T; Masui S; Kubota N; Yamada K; Kobayashi A; Kishii K
J Radiat Res; 2005 Sep; 46(3):363-72. PubMed ID: 16210793
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas.
Matsuoka H; Shibamoto Y; Kubota T; Tsujitani M; Majima T
Oncol Rep; 2000; 7(1):23-6. PubMed ID: 10601585
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
Shibamoto Y; Kubota T; Kishii K; Tsujitani M
Radiother Oncol; 2000 Aug; 56(2):265-70. PubMed ID: 10927148
[TBL] [Abstract][Full Text] [Related]
5. Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells.
Aoki M; Furusawa Y; Shibamoto Y; Kobayashi A; Tsujitani M
J Radiat Res; 2002 Jun; 43(2):161-6. PubMed ID: 12238330
[TBL] [Abstract][Full Text] [Related]
6. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
Murata R; Tsujitani M; Horsman MR
Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
Nishimura Y; Nakagawa K; Takeda K; Tanaka M; Segawa Y; Tsujino K; Negoro S; Fuwa N; Hida T; Kawahara M; Katakami N; Hirokawa K; Yamamoto N; Fukuoka M; Ariyoshi Y
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):786-92. PubMed ID: 17512126
[TBL] [Abstract][Full Text] [Related]
8. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.
Yasui H; Asanuma T; Kino J; Yamamori T; Meike S; Nagane M; Kubota N; Kuwabara M; Inanami O
BMC Cancer; 2013 Mar; 13():106. PubMed ID: 23496909
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
Kavanagh BD; Khandelwal SR; Schmidt-Ullrich RK; Roberts JD; Shaw EG; Pearlman AD; Venitz J; Dusenbery KE; Abraham DJ; Gerber MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1133-9. PubMed ID: 11240256
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy.
Shibamoto Y; Takahashi M; Abe M
Radiother Oncol; 1996 Jul; 40(1):55-8. PubMed ID: 8844888
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study.
Karasawa K; Sunamura M; Okamoto A; Nemoto K; Matsuno S; Nishimura Y; Shibamoto Y
Radiother Oncol; 2008 Jun; 87(3):326-30. PubMed ID: 18342968
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Bernier J; Stratford MR; Denekamp J; Dennis MF; Bieri S; Hagen F; Kocagöncü O; Bolla M; Rojas A
Radiother Oncol; 1998 Aug; 48(2):123-33. PubMed ID: 9783883
[TBL] [Abstract][Full Text] [Related]
13. The radiosensitizing effect of doranidazole on human colorectal cancer cells exposed to high doses of irradiation.
Zhang L; Gong A; Ji J; Wu Y; Zhu X; Lv S; Lv H; Sun X
BMC Cancer; 2007 Oct; 7():188. PubMed ID: 17919337
[TBL] [Abstract][Full Text] [Related]
14. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350).
Kuwabara M; Iida Y; Inanami O; Sawamura S; Yokoyama K; Tsujitani M
J Radiat Res; 2002 Mar; 43(1):77-88. PubMed ID: 12056332
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
Shulman LN; Buswell L; Riese N; Doherty N; Loeffler JS; von Roemeling RW; Coleman CN
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):349-53. PubMed ID: 10760430
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
17. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.
Bradley KA; Pollack IF; Reid JM; Adamson PC; Ames MM; Vezina G; Blaney S; Ivy P; Zhou T; Krailo M; Reaman G; Mehta MP;
Neuro Oncol; 2008 Oct; 10(5):752-8. PubMed ID: 18715950
[TBL] [Abstract][Full Text] [Related]
18. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
19. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Koukourakis MI; Giatromanolaki A; Schiza S; Kakolyris S; Georgoulias V
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):107-14. PubMed ID: 9989521
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
